These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interleukin-23 receptor genetic polymorphisms and Crohn's disease susceptibility: a meta-analysis.
    Author: Li Y, Mao Q, Shen L, Tian Y, Yu C, Zhu WM, Li JS.
    Journal: Inflamm Res; 2010 Aug; 59(8):607-14. PubMed ID: 20157760.
    Abstract:
    OBJECTIVE: This study was designed to evaluate whether interleukin-23 receptor (IL-23R) polymorphisms were associated with Crohn's disease (CD) susceptibility. METHODS: PubMed, MEDLINE, and Embase were searched for studies that investigated the IL-23R variants and CD risk. Meta-analysis from all eligible case-control studies was performed to assess the purported associations. RESULTS: Our analysis found that variant minor alleles for single nucleotide polymorphisms (SNPs) rs11209026 (Arg381Gln) (P < 0.00001, OR = 0.43, 95% CI (0.37-0.50)) and rs7517847 (G/G vs. T/T, P < 0.00001, OR = 0.49, 95% CI (0.38-0.64); G/G vs. T/G + T/T, (P < 0.00001, OR = 0.56, 95% CI (0.44-0.72); T/G + G/G vs. T/T, (P < 0.00001, OR = 0.71, 95% CI (0.64-0.79) of IL-23R were inversely associated with CD risk; sensitivity analysis also indicated that Caucasian population with a variant of Arg381Gln has a decreased risk for developing CD (P < 0.00001, OR = 0.43, 95% CI (0.36-0.50)). CONCLUSION: Our meta-analysis supports that two polymorphisms (Arg381Gln and rs7517847) within the IL-23R gene may be considered to be protective factors against developing CD. Further large case-control studies especially concerning ethnicity differences and genotype-phenotype interaction should be performed to clarify possible roles of IL-23R in CD.
    [Abstract] [Full Text] [Related] [New Search]